Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

The Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial (NCT01631214; https://clinicaltrials.gov/ct2/show/NCT01631214) showed that romosozumab for 1 year followed by alendronate led to larger areal bone mineral density (aBMD) gains and superior fractu...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Jacques P., Engelke, Klaus, Keaveny, Tony M., Chines, Arkadi, Chapurlat, Roland, Foldes, A. Joseph, Nogues, Xavier, Civitelli, Roberto, De Villiers, Tobias, Massari, Fabio, Zerbini, Cristiano A.F., Wang, Zhenxun, Oates, Mary K., Recknor, Christopher, Libanati, Cesar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292813/
https://www.ncbi.nlm.nih.gov/pubmed/34190361
http://dx.doi.org/10.1002/jbmr.4409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292813/
https://www.ncbi.nlm.nih.gov/pubmed/34190361
http://dx.doi.org/10.1002/jbmr.4409

Ejemplares similares